Proton pump inhibitors are built around a benzimidazole linked through a sulfoxide bridge to a pyridine. Because the active API is a sulfoxide, every route contains a selective oxidation step, and dimethyl sulfoxide serves as both solvent and oxidant in several industrial processes.
The Sulfide-to-Sulfoxide Step
The penultimate step oxidizes a 2-[(pyridylmethyl)thio]benzimidazole to the sulfoxide and must stop there, holding the sulfone below about 0.5–1.0%. DMSO-based systems favor the first oxidation and slow the second, giving high conversion within the pharmacopeial impurity limit. DMSO also supports upstream benzimidazole cyclization at 120–160 °C and alkoxide SNAr steps that introduce pantoprazole and rabeprazole alkoxy substituents.
| System | Activating reagent | Temperature |
|---|---|---|
| Thermal DMSO | None | 40–80 °C |
| Albright–Goldman | Acetic anhydride | 0–25 °C |
| Swern-type | Oxalyl chloride | −78 °C |
| DMSO + TFAA | Trifluoroacetic anhydride | −30 to 0 °C |
Table 1: DMSO-based sulfide-to-sulfoxide oxidation systems
Stronger oxidants such as m-chloroperbenzoic acid are fast but tend to over-oxidize and vary from batch to batch. HPLC monitoring lets the batch be quenched the moment target conversion is reached, so the sulfone stays within the pharmacopeial limit while unreacted sulfide is minimized. The table above summarizes the principal activation options, which differ in temperature and sulfoxide selectivity.
Upstream Steps and Chiral Oxidation
Beyond the final oxidation, DMSO appears earlier in PPI assembly. The substituted benzimidazole is constructed by condensation and cyclization in DMSO at 120–160 °C, where it dissolves the polar diamine and promotes ring closure without strongly acidic conditions. Pantoprazole and rabeprazole carry alkoxy substituents introduced by SNAr displacement on a chloropyridine, with DMSO accelerating the reaction by solubilizing the alkoxide at 60–100 °C.
For single-enantiomer esomeprazole, the sulfoxide carbon is a stereogenic center, so the oxidation must be both enantioselective and sulfoxide-selective. The established route uses a titanium(IV) isopropoxide–tartrate catalyst with cumene hydroperoxide in low-water DMSO, which dissolves the titanium complex and substrate while staying inert to the peroxide. Because all DMSO stages lie within the API chain, pharmaceutical-grade DMSO is specified and residual DMSO is controlled as a Class 3 solvent under ICH Q3C.
Why DMSO over Other Oxidant Solvents
Stronger peracid oxidants oxidize quickly but over-oxidize and vary batch to batch; DMSO-based oxidation is milder and more controllable. DMSO tolerates the moisture-sensitive titanium catalyst and the cumene hydroperoxide terminal oxidant without competing decomposition. It is a Class 3 solvent under ICH Q3C, and vonoprazan, a newer potassium-competitive acid blocker, still uses DMSO for its SNAr and condensation stages.
References
- Albright, J.D.; Goldman, L. J. Am. Chem. Soc., 1965, 87(19), 4214–4216.
- Mancuso, A.J.; Swern, D. Synthesis, 1981, 165–185.
- ICH Harmonised Tripartite Guideline Q3C(R6), 2019.